Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564821 | 0.93 | LRRK2 (0.73) | LRRK2CYP1A2 | |
| SCHEMBL4561209 | 0.90 | LRRK2 (0.79) | LRRK2CYP1A2 | |
| SCHEMBL5021352 | 0.89 | LRRK2 (1.00) | LRRK2CYP1A2 | |
| SCHEMBL19729811 | 0.86 | LRRK2 (0.64) | LRRK2CYP1A2 | |
| SCHEMBL5021023 | 0.84 | LRRK2 (0.62) | LRRK2CYP1A2 | |
| SCHEMBL24400101 | 0.83 | LRRK2 (0.62) | LRRK2CYP1A2 | |
| SCHEMBL4559418 | 0.83 | LRRK2 (0.89) | LRRK2CYP1A2 | |
| SCHEMBL19729804 | 0.83 | LRRK2 (0.65) | LRRK2CYP1A2 | |
| SCHEMBL20414129 | 0.83 | LRRK2 (0.65) | LRRK2CYP1A2 | |
| SCHEMBL19733840 | 0.83 | LRRK2 (0.65) | LRRK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | claimed |
| EP-2638031-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3124483-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | claimed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-11834439-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11591316-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3998261-A1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3472153-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11111235-B2 | Compounds, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20140228384-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH INC (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2646819-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | Genentech, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075046-A9 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012075046-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002260-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
| US-20230227436-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
| US-11591316-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
| US-11834439-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
| US-20220135546-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885CYP1A2 3177/4885 |
| US-11111235-B2 | Compounds, compositions, and methods | LRRK2, SNCA, PARK7 | LRRK2 1/4885CYP1A2 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.